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BACKGROUND
	 •		Nilotinib is a tyrosine kinase inhibitor (TKI) for the treatment of adult 
patients with newly diagnosed Philadelphia chromosome positive 
(Ph+) chronic myeloid leukaemia (CML) in chronic phase.
	 •		The ENESTnd phase III trial demonstrated that nilotinib has clinical 
superiority over current standard treatment of first-line imatinib 
in patients with chronic phase Ph+ CML, on the basis that fewer 
patients progressed to accelerated phase/blast crisis.[1,2]
	 •		Within this trial, significantly fewer patients progressed on nilotinib 
300 mg BD (0.7% patients, p=0.003) or nilotinib 400 mg BD (1.8% 
patients, p=0.0089) compared to imatinib 400 mg OD (6.0% 
patients).[1,2]
	 •		Whilst the clinical benefits of nilotinib have been demonstrated, the 
cost-effectiveness of first-line nilotinib has not been explored.
OBJECTIVES
	 •		To evaluate the cost-effectiveness of first-line nilotinib compared to 
first-line imatinib for patients newly diagnosed with chronic phase 
Ph+ CML.
	 •		Population: Adult patients with Ph+ CML diagnosed in chronic 
phase and who do not initially receive a stem cell transplant (SCT).
	 •		Intervention: First-line nilotinib 300 mg BD, second-line dasatinib 
100 mg OD.
	 •		Comparator: First-line imatinib 400 mg OD, second-line dasatinib 
100mg OD.
	 •		Outcomes: Costs, life-years (LYs), quality-adjusted life-years 
(QALYs), incremental cost effectiveness ratios (ICERs). 
METHODS
	 •		A Markov state-transition model based on the 24 month follow-up 
from the ENESTnd randomised controlled trial was developed to 
simulate the transitions of a hypothetical cohort of chronic phase 
CML patients over a lifetime (Figure 1). The clinical effectiveness 
of first-line treatment was modelled by extrapolating time on 
treatment data from the ENESTnd trial using a Weibull curve.
	 •		Health-related quality of life: EQ-5D utilities were applied to 
patients in each health state (Figure 1) and utility decrements were 
estimated for patients experiencing severe (grade 3 and 4) adverse 
events on TKI therapy (Table 1).
	 •		Costs: Costs (Sterling, 2011) associated with the different drug 
therapies, allogeneic stem cell transplantation (allo-SCT), routine 
hospital appointments for administration and monitoring, and 
treatment for severe adverse events were included. A patient 
access scheme is available for first-line nilotinib therapy and was 
included in the analysis.
	 •		Perspective: UK National Health Service (NHS) and Personal 
Social Services (PSS).
	 •		Discount rate: Future costs and benefits were discounted by 
3.5% to reflect society’s time preference.
	 •		Probabilistic sensitivity analysis (PSA): All uncertain model 
parameters were simultaneously sampled from their probability 
distribution in order to provide a mean estimate of the costs, 
survival and QALYs. Extensive one-way sensitivity analyses 
were also performed to evaluate the impact of varying baseline 
estimates and assumptions.
Table 1. Treatment costs, utilities and disutilities included in the model
Parameter Value Source
Costs
Nilotinib 300 mg BD (28 days) £2,432.85 [3]
Imatinib 400 mg OD (30 days) £1,724.39 [4]
Dasatinib 100 mg OD (30 days) £2,504.96 [4]
HU 500mg (25 days) £10.47 [4]
Allogeneic SCT £99,224.38 [5,6]
Utilities
Chronic phase utility 0.854 [7]
Accelerated phase utility 0.595 [7]
Blastic phase utility 0.595 [7]
Transplant utility 0.813 Calculated*
Disutilities
Nilotinib disutility 0.010 Calculated*
Imatinib disutility 0.016 Calculated*
HU disutility 0 Assumption
Dasatinib disutility 0.019 Calculated*
*Based on the frequency and duration of serious adverse events.  
 HU = hydroxyurea; SCT = stem cell transplantation.
Figure 1. Treatment pathways and health states in cost-effectiveness model
RESULTS
	 •		Overall survival is estimated to be consistently greater in the 
nilotinib arm than the imatinib arm for all time points.
	 •		Figure 2 presents the modelled overall survival of patients in the 
nilotinib arm and depicts the transition of patients through each 
of the health states. The orange area represents the number of 
patients alive on first-line nilotinib, with the blue dashed portion of 
the orange area representing the difference in numbers alive on 
first-line nilotinib compared to first-line imatinib.
	 •		It can be seen that nilotinib has a slower rate of progression to 
worse disease health states. The overall effect is that nilotinib 
extends life in comparison to imatinib.
Table 2. Cost-effectiveness results
Parameter Life-years QALYs Lifetime costs
Undiscounted
Nilotinib 13.96 10.71 £279,000
Imatinib 13.32 10.22 £289,700
Difference 0.64 0.49 -£10,700
ICER Dominated Dominated
Discounted
Nilotinib 10.52 8.18 £220,500
Imatinib 10.17 7.90 £233,000
Difference 0.35 0.28 -£12,500
ICER Dominated Dominated  
Costs rounded to nearest hundred. ICER = incremental cost-effectiveness  
ratio; QALYs = quality-adjusted life-years.
CONCLUSIONS
 •   Our analysis suggests that first-line nilotinib provides a 
cost-effective use of NHS resources for the treatment of 
chronic phase Ph+ CML.
 •   This is in line with recent guidance from the Scottish 
Medicines Consortium (SMC) and the National Institute 
for Health and Clinical Excellence (NICE), both of whom 
have recommended nilotinib as an option for the first-
line treatment of adults with chronic phase Ph+ CML in 
Scotland and England respectively.[8,9]
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	 •		Patients receiving first-line nilotinib followed by second-line 
dasatinib are estimated to live an additional 0.64 years (33 weeks) 
compared to the imatinib arm, with an associated cost saving of 
£10,700 over a lifetime (Table 2).
	 •		The mean undiscounted survival in the nilotinib arm is estimated to 
be 13.96 years compared to 13.32 years in the imatinib arm.
	 •		After adjusting for quality of life, patients are estimated to gain an 
additional 0.49 QALYs in the nilotinib arm compared to the imatinib 
arm.
	 •		After discounting, patients are estimated to accrue an additional 
0.35 LYs and 0.28 QALYs in the nilotinib arm compared to the 
imatinib arm. Expected lifetime (discounted) costs in the nilotinib 
arm are £220,416 compared to £232,941 in the imatinib arm.
	 •		The nilotinib arm therefore dominates the imatinib arm as it is 
more effective and less costly.
	 •	 In all of the sensitivity analyses, first-line nilotinib remained 
cost-effective at a threshold of £20,000 per QALY gained 
compared with imatinib, with nilotinib dominating imatinib in the 
majority of cases.
Patients may die from other causes at any time. CP = chronic phase; AP = accelerated phase; BC = blast crisis; 
allo-SCT = allogeneic stem cell transplantation; HU = hydroxyurea.
Presented at the 17th Congress of EHA, Amsterdam, The Netherlands, 16th June 2012.
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Figure 2. Estimated survival for patients receiving first-line nilotinib 
followed by second-line dasatinib
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